These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35576048)

  • 1. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
    Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
    Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
    Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
    Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
    Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
    Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
    Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
    Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics.
    Kolb M; Flaherty KR; Silva RS; Prasse A; Vancheri C; Mueller H; Sroka-Saidi K; Wells AU;
    Adv Ther; 2023 Dec; 40(12):5536-5546. PubMed ID: 37751022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung function outcomes in the INPULSIS
    Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
    Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural history of progressive fibrosing interstitial lung diseases.
    Brown KK; Martinez FJ; Walsh SLF; Thannickal VJ; Prasse A; Schlenker-Herceg R; Goeldner RG; Clerisme-Beaty E; Tetzlaff K; Cottin V; Wells AU
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32217654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
    Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
    BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
    Richeldi L; Crestani B; Azuma A; Kolb M; Selman M; Stansen W; Quaresma M; Stowasser S; Cottin V
    Respir Med; 2019 Sep; 156():20-25. PubMed ID: 31404749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
    N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
    Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
    Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
    Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
    Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.